A meta-analysis of individual patient data compiled evidence for intravenous phage therapy in difficult-to-treat infections across nine high-income countries. The pooled estimates suggested a 65.8% probability of clinical improvement and 55.3% probability of microbiological eradication, with an estimated adverse reaction probability of 9.2% among monitored patients. The authors stressed that the evidence base remains heterogeneous—dominated by uncontrolled studies and case reports—and emphasized that route-specific comparisons should be interpreted cautiously. For antimicrobial strategy teams, the takeaway is that systemic phage delivery is edging toward quantitative synthesis, but stronger controlled trials are still needed to define where phage fits alongside standard-of-care antibiotics.